The relapse rate among patients with relapsing-remitting multiple sclerosis who were treated with rituximab was higher than among those treated with ocrelizumab, results of a noninferiority study suggest.
Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival benefits with 1 year of venetoclax plus obinutuzumab versus a chemotherapy-based regimen.
The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and newly approved agents and combination therapies.
In the second-line setting of head and neck cancer, metronomic triple therapy outperformed clinician choice chemotherapy in both progression-free survival and overall survival.
Radiation therapy may be safely omitted for patients with primary mediastinal B-cell lymphoma (PMBCL) who achieved a complete metabolic response after immunochemotherapy.